ZAVENTEM, Belgium--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) today announced that the European Commission has granted the company marketing authorization for Cytopoint (lokivetmab), the first monoclonal ...
Lokivetmab (Cytopoint) is an FDA-approved shot your vet can give your dog to treat itching and skin inflammation (dermatitis) that’s usually caused by allergies. Allergens like pollen, dust particles, ...
A month has gone by since the last earnings report for Zoetis (ZTS). Shares have lost about 0.8% in that time frame, outperforming the S&P 500. Will the recent negative trend continue leading up to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback